General Hospital Psychiatry
Volume 27, Issue 5 , Pages 329-337 , September 2005

A cognitive therapy conceptualization of panic disorder exacerbated by interferon treatment

  • Guy A. Farber, M.D.

      Affiliations

    • Department of Consultation and Liaison Psychiatry, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
    • Corresponding Author InformationCorresponding author. Tel.: +44 718 268 7289; fax: +44 718 544 1735.
    • ,
  • Tomer Levin, M.D.

      Affiliations

    • Department of Consultation and Liaison Psychiatry, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
    • ,
  • Craig A. White, Clin.Psy.D., Ph.D.

      Affiliations

    • Consulting and Clinical Psychology Services, NHS Ayrshire and Arran, Ayrshire Central Hospital, Irvine, KA12 8SS Scotland, UK
    • Faculty of Medicine, University of Glasgow, G12 0XH Scotland, UK

Received 18 February 2005 ,Accepted 23 May 2005.

References 

  1. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry. 2003;64:708–714
  2. Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001;105:45–55
  3. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961–966
  4. Beck AT, Brown G, Epstein N, Steer RA. An inventory for measuring anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893–897
  5. Beck AT, Steer RA, Garbin MG. Psychometric properties of the beck depression inventory: twenty five years of evaluation. Clin Psychol Rev. 1988;8:77
  6. Raymond SK. Hepatitis C virus. In:  Sherwood LG,  John GB,  Neil RB editor. Infectious diseases. Philadelphia: Lippincott Williams and Wilkins; 2004;p. 2072
  7. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26:62S–65S
  8. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485–1492
  9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965
  10. Fontana RJ, Schwartz SM, Gebremariam A, Lok AS, Moyer CA. Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics. 2002;43:378–385
  11. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther. 2002;16:1091–1099
  12. Maes M, Bonaccorso S. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C. Acta Psychiatr Scand. 2004;109:126–131
  13. Gochee PA, Powell EE, Purdie DM, Pandeya N, Kelemen L, Shorthouse C, et al. Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C. Psychosomatics. 2004;45:49–57
  14. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, et al. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54:906–914
  15. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol. 2002;22:86–90
  16. Westra HA, Stewart SH. Cognitive behavioural therapy and pharmacotherapy: complementary or contradictory approaches to the treatment of anxiety?. Clin Psychol Rev. 1998;18:307–340
  17. Spiegel DA, Bruce TJ. Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials. Am J Psychiatry. 1997;154:773–781
  18. Butler AC, Beck JS. Cognitive therapy outcomes: a review of meta-analyses. J Norw Psychol Assoc. 2000;37:1–9
  19. Landon TM, Barlow DH. Cognitive-behavioral treatment for panic disorder: current status. J Psychiatr Pract. 2004;10:211–226
  20. Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry. 1994;164:759–769
  21. Klosko JS, Barlow DH, Tassinari R, Cerny JA. A comparison of alprazolam and behavior therapy in treatment of panic disorder. J Consult Clin Psychol. 1990;58:77–84
  22. Beck AT, Sokol L, Clark DA, Berchick R, Wright F. A crossover study of focused cognitive therapy for panic disorder. Am J Psychiatry. 1992;149:778–783
  23. Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry. 1993;50:44–50
  24. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev. 1995;15:819–844
  25. Oei TPS, Llamas M, Devilly GJ. The efficacy and cognitive processes of cognitive behaviour therapy in the treatment of panic disorder with agoraphobia. Behav Cogn Psychother. 1999;27:63–88
  26. Otto MW, Deveney C. Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. J Clin Psychiatry. 2005;66(Suppl 4):28–32
  27. Clark DM. A cognitive approach to panic. Behav Res Ther. 1986;24:461–470
  28. Kamieniecki GW, Wade T, Tsourtos G. Interpretive bias for benign sensations in panic disorder with agoraphobia. J Anxiety Disord. 1997;11:141–156
  29. Exton MS, Baase J, Pithan V, Goebel MU, Limmroth V, Schedlowski M. Neuropsychological performance and mood states following acute interferon-beta-1b administration in healthy males. Neuropsychobiology. 2002;45:199–204
  30. Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol. 2004;18:41–46

PII: S0163-8343(05)00074-5

doi: 10.1016/j.genhosppsych.2005.05.012

General Hospital Psychiatry
Volume 27, Issue 5 , Pages 329-337 , September 2005

Article Tools